TearSolutions
Phase 1/2NATURAL THERAPY FOR OCULAR SURFACE DISEASE TearSolutions has developed LacripepTM, a proprietary first-in-class peptide therapy Read Lacripep’s FIH Study in CORNEA Request More Information View Press Releases Scientific Publications Developing Potentially Disruptive Therapies for the Treatment of Ocular Surface Related Diseases Background The quality of human tear film is critical for corneal epithelial and neuronal […]
About
NATURAL THERAPY FOR OCULAR SURFACE DISEASE TearSolutions has developed LacripepTM, a proprietary first-in-class peptide therapy Read Lacripep’s FIH Study in CORNEA Request More Information View Press Releases Scientific Publications Developing Potentially Disruptive Therapies for the Treatment of Ocular Surface Related Diseases Background The quality of human tear film is critical for corneal epithelial and neuronal […]
Funding History
1Total raised: $2.5M
Company Info
Contact
Sectors
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile